The shadow of generic rivalry has repeatedly loomed around copyright’s famous drug, PDE5 Inhibitor, raising questions about the future of connected drug stakes. While early times saw significant profits, the intellectual property expiration has allowed the path for discounted alternatives, possibly reducing profitability and presenting a genuine